State Street Corp raised its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 0.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 121,422,392 shares of the company's stock after purchasing an additional 1,009,136 shares during the quarter. State Street Corp owned 4.93% of Merck & Co., Inc. worth $17,745,131,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Cornerstone Select Advisors LLC raised its holdings in Merck & Co., Inc. by 2.8% during the third quarter. Cornerstone Select Advisors LLC now owns 26,249 shares of the company's stock worth $3,814,000 after purchasing an additional 726 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. boosted its stake in Merck & Co., Inc. by 90.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,784 shares of the company's stock valued at $259,000 after purchasing an additional 845 shares in the last quarter. Sumitomo Life Insurance Co. boosted its stake in Merck & Co., Inc. by 150.5% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 57,534 shares of the company's stock valued at $8,360,000 after purchasing an additional 34,566 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Merck & Co., Inc. by 69.5% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 222 shares of the company's stock valued at $32,000 after purchasing an additional 91 shares during the period. Finally, TIAA CREF Individual & Institutional Services LLC increased its position in shares of Merck & Co., Inc. by 10.4% during the 3rd quarter. TIAA CREF Individual & Institutional Services LLC now owns 128,498 shares of the company's stock valued at $18,672,000 after purchasing an additional 12,109 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.
Merck & Co., Inc. Trading Up 0.6%
NYSE MRK opened at $133.56 on Friday. Merck & Co., Inc. has a twelve month low of $95.36 and a twelve month high of $156.92. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35. The stock has a market cap of $329.26 billion, a price-to-earnings ratio of 137.69, a PEG ratio of 6.62 and a beta of 0.13. The firm's 50 day moving average price is $145.28 and its two-hundred day moving average price is $129.29.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.09 by $0.40. The company had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. During the same quarter in the prior year, the company earned $2.58 earnings per share. The company's revenue for the quarter was up 4.7% on a year-over-year basis. Equities analysts anticipate that Merck & Co., Inc. will post 2.82 EPS for the current year.
Merck & Co., Inc. Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Tuesday, December 15th. This is a boost from Merck & Co., Inc.'s previous quarterly dividend of $0.85. Merck & Co., Inc.'s dividend payout ratio is 350.52%.
Analysts Set New Price Targets
Several analysts have recently weighed in on MRK shares. Weiss Ratings upgraded Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 25th. Citigroup lifted their target price on Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a "neutral" rating in a report on Monday, October 12th. Morgan Stanley dropped their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an "overweight" rating on the stock in a research report on Wednesday, October 7th. TD Cowen upped their price target on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the company a "hold" rating in a report on Wednesday, September 23rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Merck & Co., Inc. from $165.00 to $175.00 and gave the company an "overweight" rating in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $155.74.
Check Out Our Latest Report on Merck & Co., Inc.
Key Merck & Co., Inc. News
These are some of the MRK news items that stood out recently:
Insiders Place Their Bets
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of Merck & Co., Inc. stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the transaction, the executive vice president owned 112,955 shares of the company's stock, valued at $16,718,469.55. The trade was a 34.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.17% of the stock is currently owned by company insiders.
Merck & Co., Inc. Profile
(
Free Report)
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Further Reading
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.